Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -5.86 is 18% below its 5-year average of -4.97, near the high end of its 5-year range (-14.40–-2.25).
58.16% below its 12-month average of -3.71.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -1.52.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 22 comparable quarters.
EARNINGS PER SHARE (EPS)
-5.86
EARNINGS PER SHARE (EPS) AVG TTM
-3.71
EARNINGS PER SHARE (EPS) AVG 3Y
-3.25
EARNINGS PER SHARE (EPS) AVG 5Y
-4.97
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-58.16%
CURRENT VS 3Y AVG
-80.17%
CURRENT VS 5Y AVG
-17.83%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Vera Therapeutics, Inc.
Market Cap
$2.11B
Earnings Per Share (EPS)
-5.86
TTM Avg
-3.71
3Y Avg
-3.25
5Y Avg
-4.97
Market Cap
$2.11B
Earnings Per Share (EPS)
5.70
TTM Avg
4.76
3Y Avg
4.08
5Y Avg
3.55
Market Cap
$2.11B
Earnings Per Share (EPS)
-0.21
TTM Avg
-0.38
3Y Avg
-1.05
5Y Avg
-1.28
Market Cap
$2.13B
Earnings Per Share (EPS)
-3.62
TTM Avg
-1.33
3Y Avg
-15.88
5Y Avg
-28.60
Market Cap
$2.06B
Earnings Per Share (EPS)
-3.53
TTM Avg
-3.65
3Y Avg
-4.13
5Y Avg
-9.06
Market Cap
$2.06B
Earnings Per Share (EPS)
-4.36
TTM Avg
-3.17
3Y Avg
-2.92
5Y Avg
-2.56
Market Cap
$2.17B
Earnings Per Share (EPS)
-0.54
TTM Avg
-0.98
3Y Avg
-0.30
5Y Avg
0.08
Market Cap
$2.05B
Earnings Per Share (EPS)
0.47
TTM Avg
0.27
3Y Avg
0.03
5Y Avg
0.00
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | $2.11B | -5.86 | -3.71 | -3.25 | -4.97 |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 5.70 | 4.76 | 4.08 | 3.55 |
| SELLAS Life Sciences Group, Inc. (SLS)vs › | $2.11B | -0.21 | -0.38 | -1.05 | -1.28 |
| GeneDx Holdings Corp. (WGS)vs › | $2.13B | -3.62 | -1.33 | -15.88 | -28.60 |
| Alvotech (ALVO)vs › | $2.08B | -0.63 | -0.39 | -1.45 | -2.42 |
| Viridian Therapeutics, Inc. (VRDN)vs › | $2.06B | -3.53 | -3.65 | -4.13 | -9.06 |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.06B | -4.36 | -3.17 | -2.92 | -2.56 |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.17B | -0.54 | -0.98 | -0.30 | 0.08 |
| Vericel Corporation (VCEL)vs › | $2.05B | 0.47 | 0.27 | 0.03 | 0.00 |
| Pharvaris N.V. (PHVS)vs › | $2.17B | -3.14 | -3.03 | -2.85 | -2.34 |
Trailing EPS (TTM)
$-5.86
Forward EPS (Est.)
$-6.24
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -4.66 |
| 2024-12-31 | -2.75 |
| 2023-12-31 | -2.25 |
| 2022-12-31 | -3.35 |
| 2021-12-31 | -2.43 |
| 2020-12-31 | -14.40 |
| 2019-12-31 | -3.46 |
